Appetite Suppressant and Fat Binder Qualities
Clinical Research into NeOpuntia
No other non-prescription pills, claiming to help people to reduce weight or cure obesity have ever been subjected to this level of professional, medical scrutiny.
Why?
Because they know they'd fail!
By taking Proactol pills, in accordance with the instructions, then an overweight or obese person should be able to gradually reduce his/her body weight to a level approaching normality,
providing they also make two very important life-style changes - take regular exercises and eat a more nutritionally healthy and balanced diet.
The overall summary of the findings of these four research projects is that after eating a meal and then taking a pill containing NeOpuntia, between 27% and 28% of the total fat taken in with the meal is not stored or retained in the body, but is passed through the body by natural means.
The findings also show that NeOpuntia is able to help control the hunger desire experienced by grossly overweight people.
Proactol also has the ability to control hunger - it acts as a very effective appetite suppressant.
More about how Proactol works and its appetite suppressant qualities....
This means that NeOpuntia, the basic ingredient of the Proactol pill, can make a huge contribution in helping people lose weight.
The volunteers were divided into two groups, one group being given a quantity of NeOpuntia, in the form of a pill, to take after every meal, the other group being given a placebo. The experiment was conducted over two 7 day periods, with a 7 day period in between when no pills were taken.
The volunteers ate the food in identical quantities over the period and the quantity of fat expelled in their faeces was carefully measured.
The results showed that those who had the NeOpuntia pills expelled more fat than those who didn't. This clearly showed that without the NeOpuntia pill, more fat from a recent meal would be stored in a person's body. NeOpuntia was seen to expel through the digestive system 27.4% of fat eaten with the meal, thus preventing this fat from being retained and stored in the body.
Project 4: Pilot Clinical Study of NeOpuntia on Fat Binding
This was a pilot study designed to determine the fat binding capacity of NeOpuntia and was carried out in France in 2003 on 10 healthy volunteers each having a normal Body Mass Index.
To carry out the test, an American breakfast recommended by the FDA, consisting of two eggs cooked in butter, two strips of bacon, two pieces of toast, two pats of butter, 4oz. of hash brown potatoes, and 8oz. of milk, was added to 2g of NeOpuntia mixed with 3g of sunflower oil and then consumed in a stomach. The amount of fat consumed was measured, and compared with the amount of fat remaining at the end of the experiment.
The same procedure was carried out on a control model using the same American breakfast, but without any NeOpuntia or sunflower oil. Again the amount of fat consumed was measured and compared with the amount of fat remaining at the end of the experiment.
The experiment showed that the amount of fat remaining in the test model was 23% less than in the control model, thereby showing that NeOpuntia has the ability to prevent or 'bind' 23% of dietary fat and prevent it from being stored in the body.
However, the researchers suggested that further testing needs to be carried out as there appeared to be an anomaly.
Project 3: Fat binding capacity of NeOpuntia in an American breakfast meal during passage through a dynamic gastrointestinal model.
The aim of this orientating type of study was to determine the fat binding capacity of NeOpuntia, added to an American breakfast, during the passage of food through a dynamic, computer-controlled model of a stomach and small intestine.
To conduct the test, a small standardized meal was added to a quantity of NeOpuntia and then consumed in a stomach. The amount of fat consumed was measured, and compared with the amount of fat remaining at the end of the experiment.
The same procedure was carried out on another model using the same standardized meal, but with the addition of an amount of chitosan product. Again the amount of fat consumed was measured and compared with the amount of fat remaining at the end of the experiment.
The experiment showed that the amount of fat remaining in the NeOpuntia model was 28.3% less than in the chitosan model, thereby showing that NeOpuntia has the ability to prevent or 'bind' 28.3% more dietary fat than a chitosan product, and prevent it from being stored in the body.
Project 2: Fat binding capacity of (competitor XXX) during passage through a dynamic gastrointestinal model.
The aim of this study was to determine the fat binding capacity of product XXX during the passage of food through a dynamic, computer-controlled model of a stomach and small intestine.
The amount of fat consumed was measured, and compared with the amount of fat remaining at the end of the experiment.
The same procedure was carried out on a control model using the same standardized meal, but without any added NeOpuntia. Again the amount of fat consumed was measured and compared with the amount of fat remaining at the end of the experiment.
The experiment showed that the amount of fat remaining in the test model was 28.3% less than in the control model, thereby showing that NeOpuntia has the ability to prevent or 'bind' 28.3% of dietary fat and prevent it from being stored in the body.
Project 1: Fat binding capacity of NeOpuntia during passage through a dynamic gastrointestinal model.
The aim of this study was to determine the fat binding capacity of NeOpuntia during the passage of food through a dynamic, computer-controlled model of a stomach and small intestine.
To conduct the test, a small standardized meal was added to a quantity of NeOpuntia and then consumed in a stomach.
The basic ingredient of Proactol is a 100% natural, 100% plant fiber product that comes from the dried and processed foliage of the
opuntia ficus indica succulent that grows in many countries throughout the world.
This product is marketed under the patented trade name of NeOpuntia®
To prove the efficiency of NeOpuntia as a fat binding product and as a product that can aid in weight loss and obesity reduction, Bio Serae, the company responsible for discovering the product, commissioned a nutritional research organization from The Netherlands - TNO Nutrition and Food Research - to undertake a clinical trial and evaluation.
Four projects were completed to underscore the efficiency of NeOpuntia - following is a summary of each project and the results:
